Lead Product(s): LB-100
Therapeutic Area: Genetic Disease Product Name: LB-100
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Lixte Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 18, 2020
Collaboration will support the preclinical studies of the potential benefit of Lixte’s proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS).